Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Gadopentetate Peptide Conjugates
Overview
Gadopentetate peptide conjugates consist of the gadolinium-based contrast agent gadopentetate dimeglumine chemically linked to targeting peptides designed to bind specific tissue markers or receptors. These hybrid molecules combine the MRI contrast properties of chelated gadolinium with the molecular specificity of peptides to enable targeted imaging of tumors, inflammatory lesions, or vascular pathology.
Mechanism of Action
Various peptide motifs including RGD sequences and somatostatin analogs have been conjugated to gadolinium chelates for preclinical evaluation.
Research Summary & Key Findings
Preclinical studies in rodent tumor models have demonstrated enhanced MRI contrast at target sites using gadopentetate-RGD and gadopentetate-somatostatin conjugates. No gadopentetate peptide conjugate has progressed to clinical use, as most targeted MRI development has focused on nanoparticle platforms or alternative chelate chemistries with improved relaxivity and safety profiles.
Clinical Status
Gadopentetate Peptide Conjugates is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Gadopentetate Peptide Conjugates"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Gadopentetate Peptide Conjugates"
Registered interventional and observational studies, including status and phase.
- PubChem: "Gadopentetate Peptide Conjugates"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Diagnostic
Pentagastrin
FDA ApprovedA synthetic pentapeptide containing the C-terminal tetrapeptide sequence of gastrin (Trp-Met-Asp-Phe-NH2) linked to beta...
View detailsDOTATATE (Ga-68)
FDA ApprovedGallium-68 DOTATATE is a radiolabeled somatostatin analog consisting of an octapeptide (Tyr3-octreotate) conjugated to t...
View detailsBombesin Analog Tracers
In Clinical TrialsBombesin analog tracers are synthetic peptides based on the 14-amino acid amphibian peptide bombesin or its mammalian co...
View detailsRGD Peptide Tracers
In Clinical TrialsRGD peptide tracers are short synthetic peptides containing the arginine-glycine-aspartic acid (RGD) tripeptide sequence...
View detailsNo lawful pathway today
Gadopentetate Peptide Conjugates is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.